Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Acquisition
Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic
Details : With the acquisition of Prometic, Kedrion has finalized a series of transactions with the announcement that it was acquiring the plasma purification plant at Laval in Québec, and the license to distribute the new product called Ryplazim in the United St...
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Undisclosed
October 18, 2021
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Acquisition
Reset All
